InflaRx presents kidney data and Needham raises InflaRx stock to Buy

Published on 10/06/2026 at 04:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Izicopan reached 90.00 percent C5a blockade over 14 days in 2026 studies. For InflaRx stock, the poster is scheduled for October 22, 2026.

IFRX, NL0012661870, Illustration mit AI erstellt.

InflaRx N.V. (ISIN NL0012661870) has secured a late-breaking Kidney Week poster session for izicopan on October 22, 2026, while Needham raised its rating to Buy on September 14, 2026. The two developments place the company's renal pipeline and clinical execution at the center of the current investment case.

Kidney data arrives October 22

According to GlobeNewswire on October 2, 2026, the American Society of Nephrology selected InflaRx for a late-breaking poster session at Kidney Week 2026 in Denver. The session is scheduled for October 22, 2026, from 10:00 a.m. to 12:00 p.m. ET.

The poster will cover izicopan, an oral C5a receptor inhibitor, in kidney disease models. InflaRx is developing the candidate for ANCA-associated vasculitis and additional renal indications, giving the October presentation a direct connection to the company's planned clinical expansion.

Izicopan shows a measurable signal

The same October 2 release reported at least 90.00 percent blockade of C5a-induced neutrophil activation over a 14-day dosing period. It also described favorable tolerability in first-in-human studies across single doses from 3 mg to 240 mg and multiple doses from 30 mg once daily to 90 mg twice daily.

InflaRx said topline Phase 2a data supported the safety profile of izicopan, while four weeks of treatment in hidradenitis suppurativa produced reductions in abscesses, nodules and draining tunnels. The company also reported reductions in the seven-day Urticaria Activity Score in chronic spontaneous urticaria, although these findings remain clinical development evidence rather than regulatory approval.

Needham rating meets market value

MarketScreener reported on September 14, 2026, that Needham raised its InflaRx rating to Buy. The rating change gives the October clinical update a market context, but the next valuation test remains tied to data quality and development progress.

InflaRx had a market capitalization of EUR 90.8 million on October 4, 2026. Its 52-week range was EUR 0.67 to EUR 2.53 on that date, a spread that illustrates the stock's sensitivity to clinical milestones and financing expectations.

Market value and investor calendar

InflaRx's next dated catalyst is the October 22, 2026 izicopan poster session. The company also lists a virtual Capital Markets Day for November 3, 2026, according to its InflaRx investor page. For investors, the key question is whether preclinical and early clinical signals can translate into a sufficiently defined renal development path.